Intraoperative Ultrasound: The Surgeon's Sixth Sense in Congenital Hyperinsulinism
"Discover how real-time ultrasound is revolutionizing tissue-sparing surgery for children with congenital hyperinsulinism, minimizing complications and maximizing cure rates."
Congenital hyperinsulinism (CHI) is a rare genetic disorder where the pancreas secretes too much insulin, leading to persistent hypoglycemia, especially in infants. This condition can cause seizures, brain damage, and developmental delays if not promptly and effectively treated. The challenge lies in identifying and removing only the affected part of the pancreas, preserving as much healthy tissue as possible.
Traditionally, surgeons relied on preoperative imaging and intraoperative palpation (feeling with their hands) to locate problematic areas within the pancreas. However, these methods can be imprecise, particularly when the lesions are small or deep within the tissue. Removing too much of the pancreas can lead to diabetes later in life, making precise surgery critical.
Enter intraoperative ultrasound (IOUS), a real-time imaging technique that allows surgeons to visualize the pancreas during the operation. Think of it as a surgeon's sixth sense, providing a live view of what lies beneath the surface. This technology promises to enhance the precision of tissue-sparing surgery, improving outcomes for children with focal CHI.
Scope and Patient Impact
Congenital hyperinsulinism is a rare derangement of glucose metabolism. One 2019 surgical review estimates its incidence at 1 to 1.4 cases per 50,000 live births, including about 80 new medically unresponsive cases in the United States each year. The same review describes a multidisciplinary model involving pediatric endocrinology, genetics, radiology, pathology, and surgery, while the 2022 HI Global Registry annual report shows how deidentified patient and caregiver surveys can reveal broader patterns of experience.
Diagnosis, Surgery, and Limits
A multidisciplinary approach can distinguish focal from diffuse congenital hyperinsulinism, localize focal lesions, and enable partial pancreatectomy that is curative in almost all focal patients. Surgery does not cure diffuse disease, although it can help prevent severe hypoglycemia and brain damage. The 2025 surgical review notes that decisions are based on medical-treatment response, imaging results, and genetic testing, while conventional imaging and invasive localization methods may present diagnostic challenges.
From Recognition to Explanation
The history materials from Charles A. Stanley, MD, describe early recognition of hypoglycemia and note January 1922 as the time when symptoms caused by low blood sugar were identified in an insulin-treated patient. Historical accounts place the first case descriptions of congenital hyperinsulinism in the 1950s. The development of the insulin radioimmunoassay by Yalow and Berson a decade later made it possible to demonstrate that persistent hypoglycemia was caused by inappropriate insulin secretion.
How Does Intraoperative Ultrasound Change the Game?
A recent study published in "Frontiers in Endocrinology" investigated the use of IOUS in guiding surgical resections for children with focal CHI. Researchers at Odense University Hospital in Denmark conducted a retrospective analysis of 24 patients with focal CHI who underwent surgery between 2010 and 2017. All patients had confirmed focal lesions via genetic testing and 18F-DOPA-PET/CT scans.
- Enhanced Localization: IOUS successfully located the focal lesion in 16 out of 20 patients (80% sensitivity).
- Improved Specificity: IOUS correctly identified the absence of focal lesions in all 11 patients with diffuse CHI (100% specificity).
- Tissue-Sparing Success: Guided by IOUS, surgeons performed tissue-sparing resections in 67% of patients, removing only the affected tissue.
- Ectopic Lesion Detection: IOUS aided in locating an ectopic lesion (a lesion outside the normal location) in the duodenal wall, a rare occurrence that can be challenging to identify.
Evidence for Intraoperative Ultrasound
Recent literature identifies intraoperative ultrasound as a tool that may help surgeons perform tissue-sparing pancreatic resection in focal congenital hyperinsulinism. A report cited in the UK perspective study found 80% sensitivity and 100% specificity for detecting focal congenital hyperinsulinism, including an ectopic lesion. A prospective, blinded study frames intraoperative ultrasound within the broader challenge of predicting focal, diffuse, or atypical disease using genetics and 18F-DOPA PET-CT.
Evidence and Complication Gaps
Evidence supporting intraoperative ultrasound includes a multicenter study whose authors identify retrospective hospital-file data and a relatively short median follow-up of 12.5 months as limitations. The same research context notes that reported prevalences were not population-based because many patients were referred after genotyping for suspected focal congenital hyperinsulinism. Separately, a 2025 retrospective single-center study analyzed complications in 74 patients undergoing 89 procedures, highlighting the need for prospective, systematic postoperative complication scoring in pediatric hyperinsulinism surgery.
Team-Based Surgical Decision Making
A surgical treatment review describes a multidisciplinary approach involving pediatric endocrinology, genetics, radiology, pathology, and surgery. According to that review, collaboration among these specialties can effectively diagnose and treat cases of congenital hyperinsulinism. The approach emphasizes coordinated evaluation rather than relying on a single specialty or isolated test.
The Future of CHI Surgery
This study adds to the growing body of evidence supporting the use of IOUS as a valuable tool in CHI surgery. By providing real-time visualization, IOUS enables surgeons to perform more precise and less invasive resections, leading to better outcomes for children with this challenging condition. The combination of genetics, advanced imaging, and innovative surgical techniques offers new hope for a future where CHI can be effectively managed with minimal long-term consequences.
Tailored Treatment and Planning
The congenital hyperinsulinism treatment market faces budgeting challenges because resource use can vary from short-focal surgery to multi-year octreotide treatment. The market analysis describes this variability as both a complication for payers and an opportunity for tailored therapeutics. Separately, an ANZSPED outlook document reports that outcomes for children are continually improving and that congenital hyperinsulinism can be managed effectively with long-term treatment.